The battle against cancer has seen remarkable advancements over the years, with immunotherapy emerging as a revolutionary approach. Despite its promise, immunotherapy faces significant hurdles including limited response rates, acquired resistance, toxicities, and high costs. This underscores the urgent need for innovative strategies in cancer treatment. Intriguingly, one of the most promising frontiers in this quest might lie within our own bodies—specifically, in the bacteria that reside within tumors.
The intriguing connection between the human microbiota and cancer isn’t a novel concept. It dates back 4,000 years when ancient observations noted that local infections could sometimes lead to tumor eradication. However, it wasn’t until the early 20th century that the oncological relevance of intratumoural microbiota gained scientific recognition. Today, we understand that these bacteria play crucial roles in both the progression and treatment of cancer, capable of either promoting or inhibiting tumor growth by altering the tumor microenvironment.
Recent research, as reviewed in an article published in Nature, has illuminated the complex interactions between intratumoural bacteria and cancer cells. These interactions can significantly influence cancer outcomes, depending on the bacterial species and the specific tumor and immune context. This understanding has paved the way for bacteria-mediated cancer immunotherapies (BCITs), a burgeoning field that leverages the unique properties of bacteria to fight cancer.
BCITs employ various mechanisms to induce tumor regression:
- Disrupting Cell Metabolism: Some bacteria can interfere with the metabolic processes of cancer cells, leading to their death.
- Inducing Apoptosis: Certain bacterial species can trigger programmed cell death in cancer cells.
- Delivering Therapeutic Agents: Genetically engineered bacteria can be used as vehicles to deliver drugs directly to tumors.
- Enhancing Immune Response: Bacteria can stimulate the body’s immune system to recognize and attack cancer cells more effectively.
The past two decades have seen significant advancements in the preclinical engineering of bacteria for cancer treatment, with some products advancing to clinical trials. Emerging BCIT strategies are particularly exciting, featuring:
- Advanced Genetic Engineering: Techniques for precise gene regulation and bacterial surface modification to enhance targeting and efficacy.
- Biohybrid Microrobots: The development of microrobots that combine biological and synthetic components to navigate the body and deliver treatments directly to tumors.
Despite the promising potential of BCITs, several challenges remain. Researchers must unravel the precise mechanisms by which bacteria affect cancer cells and the immune system. Managing adverse effects, determining optimal dosages, ensuring the sterility and safety of bacterial products, and navigating regulatory hurdles are critical steps that need to be addressed. However, the groundwork being laid by ongoing research is paving the way for the integration of BCIT into standard oncology practice.